XML 86 R62.htm IDEA: XBRL DOCUMENT
v3.24.2.u1

License, Acquisitions and Other Agreements - Acquisitions (Details) - USD ($) $ / shares in Units, $ in Thousands |  |  |  | 1 Months Ended | 2 Months Ended | 3 Months Ended | 6 Months Ended |
--- | --- | --- | --- | --- | --- | --- | --- | ---
May 03, 2024 | May 01, 2024 | Jan. 07, 2024 | May 31, 2024 | Jun. 30, 2024 | Mar. 31, 2024 | Jun. 30, 2024 | Dec. 31, 2023
License and other agreements |  |  |  |  |  |  |  |
Success-based milestone payments, based on regulatory approval |  |  |  |  | $ 185,000 |  | $ 185,000 |
Additional regulatory milestone payments |  |  |  |  | 60,000 |  | 60,000 |
Forward contract and derivative liabilities |  |  |  |  | 81,220 |  | 81,220 | $ 0
Purchase Agreement, Knopp Amendment |  |  |  |  |  |  |  |
License and other agreements |  |  |  |  |  |  |  |
Common stock issued (shares) |  |  |  | 1,872,874 |  |  |  |
Issuance of common shares, net of offering costs |  |  |  | $ 65,981 |  |  |  |
Purchase Agreement, Knopp Amendment |  |  |  |  |  |  |  |
License and other agreements |  |  |  |  |  |  |  |
Number of securities called by warrants (shares) |  | 294,195 |  |  |  |  |  |
Exercise price of warrants (in dollars per share) |  | $ 67.98 |  |  |  |  |  |
Purchase Agreement, Knopp Amendment |  |  |  |  |  |  |  |
License and other agreements |  |  |  |  |  |  |  |
Issuance of common shares, net of offering costs |  | $ 75,000 |  |  |  |  |  |
Gain on derivative |  |  |  | $ 9,239 |  |  |  |
Purchase Agreement, Knopp Amendment, 2025 Additional Consideration |  |  |  |  |  |  |  |
License and other agreements |  |  |  |  |  |  |  |
Common shares issuable, value | $ 75,000 |  |  |  |  |  |  |
Forward contract, current and written put option, current |  |  |  |  |  |  |  |
License and other agreements |  |  |  |  |  |  |  |
Forward contract and derivative liabilities | 75,220 |  |  |  |  |  |  |
Derivative Liability, 2024 Additional Consideration | Level 3 |  |  |  |  |  |  |  |
License and other agreements |  |  |  |  |  |  |  |
Fair value | 15,540 |  |  |  |  |  |  |
2024 Additional Consideration True-up | Level 3 |  |  |  |  |  |  |  |
License and other agreements |  |  |  |  |  |  |  |
Change in fair value of derivative in other income (expense), net |  |  |  |  | (590) |  |  |
Forward Contract Liability, 2025 Addtional Consideration |  |  |  |  |  |  |  |
License and other agreements |  |  |  |  |  |  |  |
Issuance of common shares, net of offering costs |  |  |  |  |  |  | 75,000 |
Forward Contract Liability, 2025 Addtional Consideration | Level 3 |  |  |  |  |  |  |  |
License and other agreements |  |  |  |  |  |  |  |
Fair value |  | $ 63,940 |  |  |  |  |  |
Change in fair value of derivative in other income (expense), net |  |  |  |  | (1,150) |  |  |
2025 Additional Consideration True-up | Level 3 |  |  |  |  |  |  |  |
License and other agreements |  |  |  |  |  |  |  |
Fair value | $ 13,810 |  |  |  |  |  |  |
Change in fair value of derivative in other income (expense), net |  |  |  |  | 1,630 |  |  |
Pyramid Biosciences, Inc. |  |  |  |  |  |  |  |
License and other agreements |  |  |  |  |  |  |  |
Upfront payment of common shares, shares (in shares) |  |  | 255,794,000 |  |  |  |  |
Upfront payment of common shares, value |  |  | $ 10,894 |  |  |  |  |
Research and development |  |  |  |  |  | $ 5,689 |  |
Common shares issuable (in shares) |  |  |  |  |  | 98,129 |  |
Pyramid Biosciences, Inc. | Developmental And Regulatory Milestones, First Asset | Lead Asset |  |  |  |  |  |  |  |
License and other agreements |  |  |  |  |  |  |  |
Success-based payments |  |  |  |  | 5,000 |  | 5,000 |
Pyramid Biosciences, Inc. | Developmental And Regulatory Milestones, Second Asset | Second Asset |  |  |  |  |  |  |  |
License and other agreements |  |  |  |  |  |  |  |
Success-based payments |  |  |  |  | 30,000 |  | 30,000 |
Pyramid Biosciences, Inc. | Commercial Sales-Based Milestones |  |  |  |  |  |  |  |
License and other agreements |  |  |  |  |  |  |  |
Success-based payments |  |  |  |  | $ 40,000 |  | $ 40,000 |

X
- Definition Acquisition, Consideration Transferred, Equity Interest Issued and Issuable + References No definition available. + Details
Name: | bhvn_AcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable
Namespace Prefix: | bhvn_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Acquisition, Consideration Transferred, Equity Interest Issued and Issuable, Shares + References No definition available. + Details
Name: | bhvn_AcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares
Namespace Prefix: | bhvn_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Acquisition, Contingent Consideration, Liability + References No definition available. + Details
Name: | bhvn_AcquisitionContingentConsiderationLiability
Namespace Prefix: | bhvn_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Additional Success-Based Milestone Payments to be Paid, Based On Regulatory Approval + References No definition available. + Details
Name: | bhvn_AdditionalSuccessBasedMilestonePaymentsToBePaidBasedOnRegulatoryApproval
Namespace Prefix: | bhvn_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Developmental Milestone, Equity Interest Issuable, Shares + References No definition available. + Details
Name: | bhvn_DevelopmentalMilestoneEquityInterestIssuableShares
Namespace Prefix: | bhvn_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Forward Contract and Derivative Liability, Current + References No definition available. + Details
Name: | bhvn_ForwardContractAndDerivativeLiabilityCurrent
Namespace Prefix: | bhvn_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Forward Contract, Obligation for Stock Issueable, Value + References No definition available. + Details
Name: | bhvn_ForwardContractObligationForStockIssueableValue
Namespace Prefix: | bhvn_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Gain on Forward Contract and Derivative Liability + References No definition available. + Details
Name: | bhvn_GainOnForwardContractAndDerivativeLiability
Namespace Prefix: | bhvn_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Success-Based Milestone Payments to be Paid, Based On Regulatory Approval + References No definition available. + Details
Name: | bhvn_SuccessBasedMilestonePaymentsToBePaidBasedOnRegulatoryApproval
Namespace Prefix: | bhvn_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Exercise price per share or per unit of warrants or rights outstanding. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details
Name: | us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details
Name: | us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1 + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3). + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details
Name: | us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details
Name: | us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of expense for research and development. Excludes cost for computer software product to be sold, leased, or otherwise marketed, writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both, and write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1 + Details
Name: | us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Number of new stock issued during the period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3 Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details
Name: | us-gaap_StockIssuedDuringPeriodSharesNewIssues
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details
Name: | us-gaap_StockIssuedDuringPeriodValueNewIssues
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=bhvn_PurchaseAgreementKnoppAmendmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ClassOfWarrantOrRightAxis=bhvn_PurchaseAgreementKnoppAmendmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsidiarySaleOfStockAxis=bhvn_PurchaseAgreementKnoppAmendmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsidiarySaleOfStockAxis=bhvn_PurchaseAgreementKnoppAmendment2025AdditionalConsiderationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForwardContractsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_DerivativeInstrumentRiskAxis=bhvn_DerivativeLiability2024AdditionalConsiderationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_DerivativeInstrumentRiskAxis=bhvn_A2024AdditionalConsiderationTrueUpMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_DerivativeInstrumentRiskAxis=bhvn_ForwardContractLiability2025AddtionalConsiderationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_DerivativeInstrumentRiskAxis=bhvn_A2025AdditionalConsiderationTrueUpMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | bhvn_AcquisitionAxis=bhvn_PyramidBiosciencesInc.Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContingentConsiderationByTypeAxis=bhvn_DevelopmentalAndRegulatoryMilestonesFirstAssetMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FairValueByAssetClassAxis=bhvn_LeadAssetMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContingentConsiderationByTypeAxis=bhvn_DevelopmentalAndRegulatoryMilestonesSecondAssetMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FairValueByAssetClassAxis=bhvn_SecondAssetMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContingentConsiderationByTypeAxis=bhvn_CommercialSalesBasedMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |